medigraphic.com
Colegio de Medicina Interna de México.

2015, Number 1

<< Back Next >>

Med Int Mex 2015; 31 (1)

Association between high 18-fluorodeoxyglucose uptake and GLUT-1 expression in thymic carcinoma

Quiroz-Castro O, Quiroz-Casian L, Quiroz-Casian N, Bourlon-de los Ríos MT, Gallegos-Garza AC, Figueroa-Badillo J, Rojas-Sotelo M, Solís-Ayala E, Bourlon-Cuellar RA

Language: Spanish
References: 25
Page: 91-98
PDF size: 497.40 Kb.


ABSTRACT

We report the case of a 60-year-old female with thymic carcinoma, which was positive for GLUT-1 on immunohistochemical analysis. 18-fluorodeoxyglucose (18-FDG) PET/CT revealed high uptake levels on the mediastinum (10.4 SUVmáx). So far 24 cases describing the association between these two phenomena in patients with thymic carcinoma have been reported in literature. It is possible that these markers are an indicator of the aggressive nature of thymus epithelial neoplasms. More evidence is needed to determine if these markers correlate with the biologic behavior of the tumor.


REFERENCES

  1. Sung YM, Lee KS, Kim B, et al. 18F-FDG PET/CT of Thymic epithelial tumors: usefulness of distinguishing and staging tumor subgroups. J Nucl Med 2006;47:1628-1634.

  2. Quint LE. Pet: Other thoracic malignancies. ICIS 2006;6:82-88.

  3. Nakajo M, Kajiya Y, Atsushi T, et al. 18 FDG PET for grading malignancy in thymic epithelial tumors: Significant differences in 18 FDG uptake and expression of glucose transporter-1 and hexokinase Ii between low and high-risk tumors: Preliminary study. EJR 2012;81:146-151.

  4. Rosado-de-Christenson ML, Strollo DC, Maram EM. Imaging of thymic epitelial neoplasm. Hematol Oncol Clin North Am 2008;22:409-431.

  5. Kojika M, Ishii G, Yoshida J, et al. Immunohistochemical differential diagnosis between thymic carcinoma and type B3 thymoma: diagnostic utility of hypoxic marker, GLUT-1, in thymic epithelial neoplasms. Mod Pathol 2009;22:1341-1350.

  6. Eng TY, Fuller CD, Jagirdar J, et al. Thymic carcinoma: State of the art review. Int J Radiat Oncol Biol Phys 2004;59:654-664.

  7. Suster S, Moran C. Histologic classification of thymoma: The World Health Organization and Beyond. Hematol Oncol Clin North Am 2008;22:381-392.

  8. Moran C, Suster S. Thymic carcinoma: current concepts and histologic features. Hematol Oncol Clin North Am 2008;22:393-407.

  9. Han HJ, Park SJ, Min HK, et al. Whole-body magnetic resonance imaging for staging metastasic thymic carcinoma. AJRCCM 2001;183:1573-1574.

  10. Marchevsky MA, McKenna RJ, Gupta R. Thymic epithelial neoplasm: A review of current concepts using an evidence-based pathology. Hematol Oncol Clin North Am 2008;22:543-562.

  11. Jóźwiak P, Lipińska A. Structure, function, and regulation of the mammalian facilitative glucose transporter gene family. Postepy Hig Med Dosw 2012;66:165-174.

  12. Ettinger DS, Riely GJ, Akerley W, et al. Thymomas and thymic carcinomas: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2013;11:562-576.

  13. Kaira K, Endo M, Shukuya T, et al. ¹⁸F-FDG uptake on PET could be a predictive marker of excision repair cross-complementation group 1 (ERCC1) expression in patients with thoracic neoplasms? Neoplasma 2012;59:257-263.

  14. Chilosi M, Iannucci A, Menestrina F, et al. Immunohistochemical evidence of active thymocyte proliferation in thymoma. Its possible role in the pathogenesis of autoimmune diseases. Am J Pathol 1987;128:464-470.

  15. Liu RS, Yeh SH, Huang MH, et al. Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of thymoma: a preliminary report. Eur J Nucl Med 1995;22:1402-1407.

  16. Kubota K, Yamada S, Kondo T, et al. PET imaging of primary mediastinal tumours. Br J Cancer 1996;73:882-886.

  17. Sasaki M, Kuwabara Y, Ichiya Y, et al. Differential diagnosis of thymic tumors using a combination of 11C-methionine PET and FDG PET. J Nucl Med 1999;40:1595-1601.

  18. El-Bawab H, Al-Sugair AA, Rafay M, et al. Role of flourine- 18 fluorodeoxyglucose positron emission tomography in thymic pathology. Eur J Cardiothorac Surg 2007;31:731- 736.

  19. Endo M, Nakagawa K, Ohde Y, et al. Utility of 18FDG-PET for differentiating the grade of malignancy in thymic epithelial tumors. Lung Cancer 2008;61:350-355.

  20. Kumar A, Regmi SK, Dutta R, et al. Characterization of thymic masses using (18)F-FDG PET-CT. Ann Nucl Med 2009;23:569-577.

  21. Shibata H, Nomori H, Uno K, et al. 18F-fluorodeoxyglucose and 11C-acetate positron emission tomography are useful modalities for diagnosing the histologic type of thymoma. Cancer 2009;115:2531-2538.

  22. Inoue A, Tomiyama N, Tatsumi M, et al. (18)F-FDG PET for the evaluation of thymic epithelial tumors: Correlation with the World Health Organization classification in addition to dual-time-point imaging. Eur J Nucl Med Mol Imaging 2009;36:1219-1225.

  23. Kaira K, Endo M, Shukuya T, et al. 18F-FDG uptake on PET could be a predictive marker of excision repair crosscomplementation group 1 (ERCC1) expression in patients with thoracic neoplasms? Neoplasma 2012;59:257-263.

  24. Igai H, Matsuura N, Tarumi S, et al. Usefulness of [18F] fluoro-2-deoxy-D-glucose positron emission tomography for predicting the World Health Organization malignancy grade of thymic epithelial tumors. Eur J Cardiothorac Surg 2011;40:143-145.

  25. Eguchi T, Yashida K, Hamanaka K, et al. Utility of 18Ffluorodeoxyglucose positron emission tomography for distinguishing between the histological types of early stage thymic epithelial tumours. Eur J Cardiothorac Surg 2012;41:1059-1062.




2020     |     www.medigraphic.com